Sign In

Alfonso Garbayo

SVP Business Development at EVERSANA

Professional Background

Alfonso Garbayo is a highly accomplished executive with a rich history in Business Development and Sales, particularly within the Life Sciences, Real World Evidence (RWE), and Health Economics and Outcomes Research (HEOR) sectors. With a robust expertise in relationship development and commercial strategies, Alfonso has become known for his skill in aligning project and program strategies with overarching business and financial objectives. His strategic mindset and analytical capabilities have allowed him to build and lead strong teams that consistently exceed performance benchmarks.

Alfonso's career trajectory showcases a variety of leadership roles, including his current position as Senior Vice President of Business Development at EVERSANA. In this role, he not only drives new revenue opportunities but also cultivates strategic partnerships that enhance the company's offerings in the healthcare landscape. His prior experience includes notable positions such as the Vice President of Strategy at HVH Precision Analytics—an EVERSANA company—and the Senior Vice President of ORION Real World Evidence HEOR at EVERSANA.

Education and Achievements

With an educational foundation that complements his professional journey, Alfonso earned his MBA from Wilmington University, where he honed his business acumen and leadership skills. Additionally, he furthered his expertise in advanced technologies during his study at the MIT Sloan School of Management, taking courses in Artificial Intelligence in Health Care. His undergraduate degree, a Bachelor of Arts from the University of Delaware, laid the groundwork for his analytical and strategic thinking.

Throughout his career, Alfonso has successfully driven numerous initiatives that have significantly contributed to the growth and operational success of the organizations he has been part of. His impressive background includes fostering complex negotiations and facilitating successful product launches, which required a keen understanding of market dynamics and organizational capabilities.

Notable Achievements

Alfonso's list of accomplishments is expansive. He has successfully identified and developed rare disease patient identification strategies, streamlined clinical trial recruitment, and cultivated C-suite advisory relationships that support the tactical and strategic growth of health-related organizations. His combination of hands-on experience in sales enablement and data integration has established him as a go-to leader in navigating the complex landscape of healthcare.

Alfonso's career has included prestigious roles, such as Director of National Accounts and Partnerships at Practice Fusion, where he was pivotal in establishing new business opportunities. His earlier experience at GE Healthcare provided him with a solid backdrop in clinical business solutions, further enhancing his capacity for impactful decision-making in executive roles.

His early days include positions with industry giants, such as Eli Lilly, where he served as an Executive Sales Representative, and Centocor, as the Manager of Sales Training. These foundational experiences equipped him with skills in hospital representation and account penetration that are critical in today’s healthcare market.

Overall, Alfonso Garbayo embodies a unique combination of strategic leadership, deep industry knowledge, and a commitment to excellence in Business Development and Sales. His journey illustrates a relentless pursuit of success that not only propels his career forward but also elevates the teams and organizations he is part of.

As Alfonso continues to navigate the ever-evolving landscape of Life Sciences and healthcare, his blend of expertise in strategy, analytics, and team leadership remains a cornerstone of his professional identity.

Highlights

Nov 2 · linkedin

The World Orphan Drug Congress concludes after four days today in Barcelona after insightful discussions and knowledge sharing among experts in rare diseases. The conference tackled various crucial aspects of rare disease drug development, shedding light on selecting new targets. This topic delved into the intricate process of identifying diseases with limited treatment options and exploring potential avenues for drug development. The event emphasized the importance of a structured approach to pinpointing these diseases, focusing on their impact on affected individuals. Discussions revolved around methodologies to assess the prevalence of these conditions in various parts of the world, including emerging markets, the US, and Europe. Experts considered innovative approaches and tools to assess rare disease treatments' cost-effectiveness and clinical efficacy, potentially speeding up their journey from the lab to the patients in need. Commercial viability was another critical point of discussion, emphasizing understanding the factors that determine whether a treatment option can sustainably reach the market. In addition to these discussions, the conference focused on enhancing access and standardizing Real-World Evidence (RWE) to facilitate rare disease research and access. This topic emphasized the importance of data transparency, sharing, and collaboration to streamline research efforts and improve patient outcomes. Throughout the conference, EVERSANA's commitment to understanding and supporting the rare disease community was underscored. The leadership team, including Pierantonio Russo MD, FCPP, FAAP, STS, Alan Crowther, Alfonso Garbayo, MBA, Charles Moon, Dan Feldman, Edward Bellringer, Marjan Manouchehri , Ph.D and, Nicolas Pietrasz and our EVERSANA Marketing Data and Analytic team played a crucial role in the discussions and interaction with the Rare Disease Community. Their dedication to research transparency, data sharing, and collaboration aligned with the theme of the event, highlighting the vital role of partnerships and collective efforts in advancing rare disease research and treatment. EVERSANA participation demonstrated our commitment to improving the lives of rare disease patients and furthering the global mission to address the unique challenges faced by these individuals. #raredisease #wodc #dataanalytics #rwe, #rwd #orphandrugs, It was a privilege to attend and participate in this year's WODC-EU conference. Conferences like these offer a ray of hope for parents and patients desperately seeking pharmaceutical companies to help treat their children's diseases. They represent a true chance for collaboration among various stakeholders to make a genuine difference.

Related Questions

How did Alfonso Garbayo leverage his expertise in strategic partnerships to enhance business development at EVERSANA?
What inspired Alfonso Garbayo to pursue an MBA at Wilmington University?
How has Alfonso Garbayo's experience at MIT Sloan School of Management shaped his approach to artificial intelligence in healthcare?
In what ways has Alfonso Garbayo utilized his sales enablement skills to drive new revenue streams in his career?
How did Alfonso Garbayo achieve success in clinical trial recruitment and rare disease patient identification during his tenure at EVERSANA?
What role did Alfonso Garbayo play in the strategic developments at HVH Precision Analytics?
How does Alfonso Garbayo's early career experience at Eli Lilly influence his leadership style today?
Alfonso Garbayo
Add to my network

Location

Greater Philadelphia